Abstract:Prion diseases are fatal neurodegenerative disorders where the formation of amyloids is thought to be infectious by templating their conformation on to natively-folded counterparts. Postulated nearly four decades ago, the search for the mechanism behind the conformational templating has proceeded to no avail. Here, we extend the thermodynamic hypothesis of protein folding (Anfinsen's dogma) to the amyloid phenomenon and illustrate that the amyloid conformation (cross-β) is one of two conformational states that are thermodynamically accessible to any protein sequence depending on concentration. A protein spontaneously assumes its native conformation below supersaturation and the amyloid cross-β conformation above supersaturation. The information to adopt the native conformation and the amyloid conformation is present in the primary sequence and the backbone of the protein, respectively, and does not require templating. The rate-limiting step for proteins to adopt the cross-β conformation of amyloid is termed nucleation, which can be catalyzed by surfaces (heterogeneous nucleation) or preformed amyloid fragments (seeding). Irrespective of the nucleation pathway, once triggered, amyloid formation proceeds spontaneously in fractal-like fashion, where the surfaces of the growing fibrils act as heterogeneous nucleation catalysts for new fibrils, a phenomenon known as secondary nucleation. This pattern is in contrast to the linear growth assumptions that the prion hypothesis necessitates for faithful prion strain replication. Additionally, the cross-β conformation buries the majority of the protein side chain inside the fibrils, making the fibrils inert, generic, and extremely stable. As such, the source of toxicity in prion disorders may come to a greater extent from the loss of proteins in their normal, soluble, and therefore functional state rather than from their transformation into stable, insoluble, nonfunctioning amyloids.

Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis

Prion-Like Mechanisms in Parkinson’s Disease

Prion-like Spreading of Disease in TDP-43 Proteinopathies

The prion-like effect and prion-like protein targeting strategy in amyotrophic lateral sclerosis

Intercellular Prion-Like Conversion and Transmission of Cu/Zn Superoxide Dismutase (SOD1) in Cell Culture

Prion-like Mechanisms in Alzheimer's Disease.

Epigenetics in the formation of pathological aggregates in amyotrophic lateral sclerosis

Co-aggregation of RNA binding proteins in ALS spinal motor neurons: evidence of a common pathogenic mechanism

Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases

The allure and pitfalls of the prion-like aggregation in neurodegeneration

Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases

The genetics and neuropathology of amyotrophic lateral sclerosis

Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases

Recent progress in prion and prion-like protein aggregation.

Protein aggregation and therapeutic strategies in SOD1- and TDP-43- linked ALS

The role of α-synuclein prion strains in Parkinson's disease and multiple system atrophy

An ALS-associated Mutation Affecting TDP-43 Enhances Protein Aggregation, Fibril Formation and Neurotoxicity

Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases

Targeting Prion-Like Protein Spreading in Neurodegenerative Diseases

Mechanism of misfolding of the human prion protein revealed by a pathological mutation

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis